Radiation Oncology Committee Meeting Agenda
Chair: Jeff Bogart

NEW

A031701 PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
Kwok

Description

**Lung Cancer**

- **AFT-16**: Induction PDL-1 inhibition Stage III NSCLC  
  **Presenter**: Urbanic

- **AFT-07**: Veliparib + ChemoRT Stage III NSCLC  
  **Presenter**: Salama

- **C30610**: Limited Stage Small Cell Intergroup Trial  
  **Presenter**: Bogart

- **NRG CC003**: PCI with or without Hippocampal Avoidance for SCLC  
  **Presenter**: Grecula

**Breast Cancer**

- **Alliance A221505**: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction  
  **Presenter**: Poppe

- **A011202**: The role of axillary lymph node dissection (cT1-3 N1) for positive sentinel lymph node disease after neoadjuvant chemotherapy

- **NRG**: Oligometastatic Trials  
  **Presenter**: Salama
CNS

- **CE.7**: SRS vs WBRT for Multiple Brain Metastases
- **A221208**: Ph IIR Radionecrosis Steroids vs Bevacizumab
- **N0577**: Ph III AG CODELETED RT + PCV vs RT+TMZ
- **A071102**: Phase II/III GBM Adjuvant TMZ ± Veliparib

**GI Cancer**

- **A021501**, “Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated RT for Borderline Resectable Adenocarcinoma of the Head of the Pancreas”
- **N 1048**: Selective use of radiation for locally advanced rectal cancer, 1,000 patients enrolled as of March 29. *Mamon*

**Skin**

- **A091605** includes stereotactic body radiotherapy and pembrolizumab in advanced [*merkel cell carcinoma*] *Chmur*

**IROC Update**